AP2948A - Thienopyrmidinedione derivatives as TRPA1 modulators - Google Patents

Thienopyrmidinedione derivatives as TRPA1 modulators

Info

Publication number: AP2948A
Authority: AP; ARIPO
Prior art keywords: thienopyrmidinedione; derivatives; trpa1 modulators; trpa1; modulators
Prior art date: 2009-03-23

Application number

AP2011005889A

Other languages

English (en)

Other versions

AP2011005889A0 (en

Inventor

Neelima Khairatkar-Joshi

Sukeerthi Kumar

Sanjay Margal

Original Assignee

Glenmark Pharamceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-23

Filing date

2010-03-23

Publication date

2014-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42780205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2948(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-23 Application filed by Glenmark Pharamceuticals Sa filed Critical Glenmark Pharamceuticals Sa

2011-10-31 Publication of AP2011005889A0 publication Critical patent/AP2011005889A0/xx

2014-07-31 Application granted granted Critical

2014-07-31 Publication of AP2948A publication Critical patent/AP2948A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AP2011005889A 2009-03-23 2010-03-23 Thienopyrmidinedione derivatives as TRPA1 modulators AP2948A (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
IN665MU2009		2009-03-23
US17135509P	2009-04-21	2009-04-21
IN2213MU2009		2009-09-23
US25199409P	2009-10-15	2009-10-15
IN2906MU2009		2009-12-16
US29447010P	2010-01-12	2010-01-12
PCT/IB2010/000930 WO2010109334A2 (fr)	2009-03-23	2010-03-23	Dérivés de thiénopyrimidinedione comme modulateurs de trpa1

Publications (2)

Publication Number	Publication Date
AP2011005889A0 AP2011005889A0 (en)	2011-10-31
AP2948A true AP2948A (en)	2014-07-31

Family

ID=42780205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2011005889A AP2948A (en)	2009-03-23	2010-03-23	Thienopyrmidinedione derivatives as TRPA1 modulators

Country Status (22)

Country	Link
US (4)	US20120178766A1 (fr)
EP (3)	EP2411395B1 (fr)
JP (2)	JP2012521406A (fr)
KR (2)	KR20110128898A (fr)
CN (3)	CN102361874A (fr)
AP (1)	AP2948A (fr)
AU (2)	AU2010227225A1 (fr)
BR (2)	BRPI1013705A2 (fr)
CA (2)	CA2756535A1 (fr)
DK (3)	DK2411395T3 (fr)
EA (2)	EA201190138A1 (fr)
ES (3)	ES2424341T3 (fr)
HU (1)	HUE024538T2 (fr)
IL (2)	IL215177A (fr)
MX (1)	MX2011009822A (fr)
PE (2)	PE20120834A1 (fr)
PL (3)	PL2411395T3 (fr)
PT (3)	PT2411395E (fr)
SG (4)	SG174398A1 (fr)
SI (3)	SI2411395T1 (fr)
WO (2)	WO2010109329A1 (fr)
ZA (2)	ZA201107649B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2756535A1 (fr)	2009-03-23	2010-09-30	Glenmark Pharmaceuticals, S.A.	Derives de furopyrimidinedione a titre de modulateurs de trpa1
PE20120774A1 (es)	2009-03-23	2012-06-27	Glenmark Pharmaceuticals Sa	COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1
UA109916C2 (uk)	2010-12-20	2015-10-26	Гленмарк Фармасьютікалс С.А.	2-аміно-4-арилтіазольні сполуки як антагоністи trра1
EP2520566A1 (fr)	2011-05-06	2012-11-07	Orion Corporation	Nouveaux composés pharmaceutiques
CN103826637A (zh) *	2011-06-13	2014-05-28	格兰马克药品股份有限公司	使用trpa1拮抗剂治疗呼吸疾患
WO2012176105A1 (fr)	2011-06-22	2012-12-27	Glenmark Pharmaceuticals Sa	Composition pharmaceutique comprenant un antagoniste du trpa1 et un antagoniste du récepteur de leucotriènes
EP2723329A1 (fr)	2011-06-22	2014-04-30	Glenmark Pharmaceuticals S.A.	Composition pharmaceutique comprenant un antagoniste de trpa1 et un agoniste de bêta-2
JP2014521634A (ja) *	2011-07-25	2014-08-28	グレンマークファーマシューティカルズ，エセ．アー．	Ｔｒｐａ１アンタゴニスト及びステロイドを含む医薬組成物
WO2013084153A1 (fr)	2011-12-05	2013-06-13	Glenmark Pharmaceuticals S.A.	Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent anticholinergique
SG11201408093PA (en) *	2012-06-08	2015-01-29	Glenmark Pharmaceuticals Sa	Amides of 2-amino-4-arylthiazole compounds and their salts
CN104822653B (zh)	2012-10-01	2017-03-08	奥赖恩公司	N‑丙‑2‑炔基甲酰胺衍生物及其作为trpa1拮抗剂的用途
EA201592120A1 (ru) *	2013-06-20	2016-04-29	Гленмарк Фармасьютикалс С.А.	Состав на основе наночастиц, содержащий антагонист trpa1
EP3057583A2 (fr) *	2013-10-15	2016-08-24	Glenmark Pharmaceuticals S.A.	Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent analgésique
WO2016023830A1 (fr) *	2014-08-11	2016-02-18	Hydra Biosciences, Inc.	Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
JP6667092B2 (ja) *	2014-08-11	2020-03-18	ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａＢｉｏｓｃｉｅｎｃｅｓ，ＬＬＣ	ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016023832A1 (fr) *	2014-08-11	2016-02-18	Hydra Biosciences, Inc.	Dérivés de thiéno- et furo[2,3-d]pyrimidine-2,4(1h,3h)-dione à titre de modulateurs des trpc5 pour le traitement des troubles neuropsychiatriques
JP6695323B2 (ja) *	2014-08-11	2020-05-20	ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａＢｉｏｓｃｉｅｎｃｅｓ，ＬＬＣ	ピリド［３，４−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
WO2016028325A1 (fr)	2014-08-22	2016-02-25	Duke University	Inhibiteurs et de trpa1 de trpv4 et procédés pour les utiliser dans des cas d'inflammation et de prurit spécifique d'un organe
US20190175599A1 (en) *	2014-09-16	2019-06-13	Glemark Pharmaceuticals S.A.	Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en)	2015-01-09	2022-01-25	Duke University	TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (fr)	2015-10-09	2017-04-13	Almirall, S.A.	Nouveaux antagonistes de trpa1
WO2017064068A1 (fr)	2015-10-14	2017-04-20	Almirall, S.A.	Nouveaux antagonistes de trpa1
JP2019513749A (ja)	2016-04-07	2019-05-30	デュークユニバーシティ	衛生化及び麻酔用のｔｒｐｖ４及びｔｒｐａ１の小分子二重阻害剤
CN110461838B (zh) *	2017-03-07	2022-05-06	豪夫迈·罗氏有限公司	噁二唑瞬时受体电位通道抑制剂
CN109422749B (zh) *	2017-08-21	2023-01-24	重庆医药工业研究院有限责任公司	一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
CN114555601B (zh)	2019-10-15	2024-04-02	勃林格殷格翰国际有限公司	新颖的四唑类
MX2023004009A (es) *	2020-10-14	2023-04-26	Boehringer Ingelheim Int	Derivados de tetrazol como inhibidores de trpa1.
CA3193606A1 (fr) *	2020-10-14	2022-04-21	Boehringer Ingelheim International Gmbh	Derives de tetrazole en tant qu'inhibiteurs de trpa1
CN116940575A (zh) *	2021-02-23	2023-10-24	深圳市康哲药业有限公司	噻吩并嘧啶二酮类化合物及其应用
US12180223B2 (en)	2021-04-14	2024-12-31	Boehringer Ingelheim International Gmbh	3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives as TRPA1 inhibitors
CN114671875A (zh) *	2022-04-27	2022-06-28	成都施贝康生物医药科技有限公司	新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) *	2022-04-27	2024-01-26	成都施贝康生物医药科技有限公司	噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
WO2025264860A2 (fr)	2024-06-18	2025-12-26	Yale University	Méthodes de traitement d'une maladie des voies respiratoires post-covid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007073505A2 (fr) *	2005-12-22	2007-06-28	Hydra Biosciences, Inc.	Méthodes et compositions de traitement de la douleur
WO2007108750A1 (fr) *	2006-03-22	2007-09-27	Astrazeneca Ab	Dérivés de pyridopyrimidine et leur utilisation comme inhibiteurs de pde4
WO2009002933A1 (fr) *	2007-06-22	2008-12-31	Hydra Biosciences, Inc.	Procédés et compositions pour le traitement de troubles

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2248231A1 (de)	1972-10-02	1974-04-11	Basf Ag	3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
SE9702001D0 (sv) *	1997-05-28	1997-05-28	Astra Pharma Prod	Novel compounds
CA2339664A1 (fr) *	1998-08-28	2000-03-09	Astrazeneca Ab	Nouveaux composes
ES2193839B1 (es)	2001-06-22	2005-02-16	Almirall Prodesfarma, S.A.	Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) *	2001-07-28	2001-09-19	Astrazeneca Ab	Novel compounds
AU2003253165A1 (en) *	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003288956A1 (en) *	2002-10-30	2004-06-07	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of rock and other protein kinases
US6890923B2 (en) *	2002-12-16	2005-05-10	Astrazeneca Ab	Compounds
US7465581B2 (en)	2002-12-18	2008-12-16	The Scripps Research Institute	ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
SE0300119D0 (sv) *	2003-01-17	2003-01-17	Astrazeneca Ab	Novel compounds
CA2536313A1 (fr)	2003-08-22	2005-03-03	Takeda Pharmaceutical Company Limited	Derive de pyrimidine fusionne et utilisation associee
EP1713815A4 (fr) *	2004-02-11	2009-03-11	Smithkline Beecham Corp	Agonistes de pth
WO2005089206A2 (fr)	2004-03-13	2005-09-29	Irm Llc	Modulateurs du canal ionique trpa1
JPWO2006083005A1 (ja)	2005-02-03	2008-06-26	武田薬品工業株式会社	縮合ピリミジン誘導体およびその用途
CA2617788A1 (fr) *	2005-08-04	2007-02-15	Apogee Biotechnology Corporation	Inhibiteurs de la sphingosine kinase et leurs methodes d'utilisation
ES2344751T3 (es) *	2005-11-08	2010-09-06	N.V. Organon	Derivados de 2-(benzoimidazol-1-il)-n-(4-feniltiazol-2-il)acetamida utiles en el tratamiento de trastornos relacionados con trpv1.
US20070105920A1 (en) *	2005-11-08	2007-05-10	Akzo Nobel N.V.	2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
WO2007054480A1 (fr) *	2005-11-08	2007-05-18	N.V. Organon	Derives bisarylique de 2-(benzimidazol-1-yl)-acetamide et leur utilisation comme inhibiteurs du recepteur trpv1
CL2008000252A1 (es)	2007-01-29	2008-03-14	Xenon Pharmaceuticals Inc	Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
KR101373794B1 (ko) *	2007-06-25	2014-03-13	샌디스크 테크놀로지스, 인코포레이티드	저장 소자들 사이에 개별적으로 제어가 가능한 차폐 플레이트들을 갖는 비휘발성 저장장치
US7951814B2 (en)	2008-06-17	2011-05-31	Glenmark Pharmaceuticals, S.A.	Quinazolinedione derivatives as TRPA1 modulators
WO2009158719A2 (fr)	2008-06-27	2009-12-30	Hydra Biosciences, Inc.	Méthodes et compositions de traitement de troubles
UA103918C2 (en)	2009-03-02	2013-12-10	Айерем Элелси	N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CA2756535A1 (fr)	2009-03-23	2010-09-30	Glenmark Pharmaceuticals, S.A.	Derives de furopyrimidinedione a titre de modulateurs de trpa1
US8623880B2 (en)	2009-03-23	2014-01-07	Glenmark Pharmaceuticals S.A.	Fused pyrimidine-dione derivatives as TRPA1 modulators
EP2411397B1 (fr)	2009-03-23	2013-05-29	Glenmark Pharmaceuticals S.A.	Dérivés d'isothiazolo-pyrimidinedione utilises comme modulateurs de la trpa1
AR076332A1 (es)	2009-04-21	2011-06-01	Boehringer Ingelheim Int	Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
AR078522A1 (es)	2009-10-15	2011-11-16	Lilly Co Eli	Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AU2010308028A1 (en)	2009-10-15	2012-04-19	Pfizer Inc.	Pyrrolo[2,3-d] pyrimidine compounds
US8440710B2 (en)	2009-10-15	2013-05-14	Hoffmann-La Roche Inc.	HSL inhibitors useful in the treatment of diabetes
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2011206621B2 (en)	2010-01-12	2016-04-14	Ab Science	Thiazole and oxazole kinase inhibitors
BR112012004154A2 (pt)	2010-07-13	2017-05-30	Novartis Ag	"derivados de oxazina e seu uso no tratamento de distúrbios neurológicos"

2010
- 2010-03-22 CA CA2756535A patent/CA2756535A1/fr not_active Abandoned
- 2010-03-22 PT PT107160509T patent/PT2411395E/pt unknown
- 2010-03-22 SG SG2011066446A patent/SG174398A1/en unknown
- 2010-03-22 SI SI201030233T patent/SI2411395T1/sl unknown
- 2010-03-22 SG SG2012069472A patent/SG184767A1/en unknown
- 2010-03-22 DK DK10716050.9T patent/DK2411395T3/da active
- 2010-03-22 KR KR1020117022604A patent/KR20110128898A/ko not_active Withdrawn
- 2010-03-22 WO PCT/IB2010/000840 patent/WO2010109329A1/fr not_active Ceased
- 2010-03-22 CN CN2010800134701A patent/CN102361874A/zh active Pending
- 2010-03-22 EP EP10716050.9A patent/EP2411395B1/fr not_active Not-in-force
- 2010-03-22 PE PE2011001704A patent/PE20120834A1/es not_active Application Discontinuation
- 2010-03-22 JP JP2012501412A patent/JP2012521406A/ja active Pending
- 2010-03-22 AU AU2010227225A patent/AU2010227225A1/en not_active Abandoned
- 2010-03-22 EA EA201190138A patent/EA201190138A1/ru unknown
- 2010-03-22 BR BRPI1013705A patent/BRPI1013705A2/pt not_active IP Right Cessation
- 2010-03-22 PL PL10716050T patent/PL2411395T3/pl unknown
- 2010-03-22 US US13/257,280 patent/US20120178766A1/en not_active Abandoned
- 2010-03-22 ES ES10716050T patent/ES2424341T3/es active Active
- 2010-03-23 PL PL13002731T patent/PL2634191T3/pl unknown
- 2010-03-23 EP EP13002731.1A patent/EP2634191B1/fr active Active
- 2010-03-23 AP AP2011005889A patent/AP2948A/xx active
- 2010-03-23 SG SG2012069530A patent/SG184769A1/en unknown
- 2010-03-23 SI SI201030891T patent/SI2634191T1/sl unknown
- 2010-03-23 PL PL10751712T patent/PL2411396T3/pl unknown
- 2010-03-23 PE PE2011001705A patent/PE20120775A1/es active IP Right Grant
- 2010-03-23 SG SG2011066503A patent/SG174404A1/en unknown
- 2010-03-23 US US12/936,451 patent/US8507503B2/en not_active Expired - Fee Related
- 2010-03-23 EA EA201190139A patent/EA022029B1/ru unknown
- 2010-03-23 WO PCT/IB2010/000930 patent/WO2010109334A2/fr not_active Ceased
- 2010-03-23 KR KR1020117022603A patent/KR101524337B1/ko not_active Expired - Fee Related
- 2010-03-23 CN CN201080013463.1A patent/CN102361877B/zh not_active Expired - Fee Related
- 2010-03-23 CA CA2756536A patent/CA2756536C/fr active Active
- 2010-03-23 PT PT107517120T patent/PT2411396E/pt unknown
- 2010-03-23 DK DK10751712.0T patent/DK2411396T3/da active
- 2010-03-23 DK DK13002731T patent/DK2634191T3/en active
- 2010-03-23 CN CN201310628814.5A patent/CN103755720B/zh not_active Expired - Fee Related
- 2010-03-23 BR BRPI1009381A patent/BRPI1009381B8/pt active IP Right Grant
- 2010-03-23 ES ES13002731.1T patent/ES2532386T3/es active Active
- 2010-03-23 JP JP2012501414A patent/JP5612070B2/ja not_active Expired - Fee Related
- 2010-03-23 HU HUE13002731A patent/HUE024538T2/hu unknown
- 2010-03-23 EP EP10751712.0A patent/EP2411396B1/fr active Active
- 2010-03-23 MX MX2011009822A patent/MX2011009822A/es unknown
- 2010-03-23 PT PT13002731T patent/PT2634191E/pt unknown
- 2010-03-23 AU AU2010227230A patent/AU2010227230B2/en not_active Ceased
- 2010-03-23 ES ES10751712T patent/ES2424342T3/es active Active
- 2010-03-23 SI SI201030231T patent/SI2411396T1/sl unknown
2011
- 2011-09-15 IL IL215177A patent/IL215177A/en not_active IP Right Cessation
- 2011-09-15 IL IL215175A patent/IL215175A/en active IP Right Grant
- 2011-10-19 ZA ZA2011/07649A patent/ZA201107649B/en unknown
- 2011-10-19 ZA ZA2011/07650A patent/ZA201107650B/en unknown
2013
- 2013-06-25 US US13/925,975 patent/US8987278B2/en active Active
2015
- 2015-02-12 US US14/620,721 patent/US9474758B2/en not_active Expired - Fee Related

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007073505A2 (fr) *	2005-12-22	2007-06-28	Hydra Biosciences, Inc.	Méthodes et compositions de traitement de la douleur
WO2007108750A1 (fr) *	2006-03-22	2007-09-27	Astrazeneca Ab	Dérivés de pyridopyrimidine et leur utilisation comme inhibiteurs de pde4
WO2009002933A1 (fr) *	2007-06-22	2008-12-31	Hydra Biosciences, Inc.	Procédés et compositions pour le traitement de troubles

Also Published As

Publication number	Publication date
CA2756535A1 (fr)	2010-09-30
US8507503B2 (en)	2013-08-13
CN102361874A (zh)	2012-02-22
EP2634191B1 (fr)	2014-12-24
IL215175A (en)	2014-01-30
CN103755720A (zh)	2014-04-30
PL2634191T3 (pl)	2015-06-30
BRPI1013705A2 (pt)	2016-04-05
HUE024538T2 (hu)	2016-01-28
US20130289054A1 (en)	2013-10-31
AU2010227230A2 (en)	2011-10-27
WO2010109334A2 (fr)	2010-09-30
PT2411396E (pt)	2013-06-06
CA2756536A1 (fr)	2010-09-30
WO2010109329A1 (fr)	2010-09-30
EP2634191A1 (fr)	2013-09-04
SG174404A1 (en)	2011-10-28
EP2411395B1 (fr)	2013-05-29
US20120295924A1 (en)	2012-11-22
ZA201107650B (en)	2012-07-25
HK1166073A1 (en)	2012-10-19
IL215177A0 (en)	2011-12-29
EA022029B1 (ru)	2015-10-30
PT2634191E (pt)	2015-03-04
SI2634191T1 (sl)	2015-04-30
ES2532386T3 (es)	2015-03-26
EA201190139A1 (ru)	2012-03-30
PL2411396T3 (pl)	2013-10-31
AU2010227230B2 (en)	2015-11-26
EP2411396A2 (fr)	2012-02-01
BRPI1009381A2 (pt)	2016-06-21
DK2411396T3 (da)	2013-08-05
IL215175A0 (en)	2011-12-29
AU2010227225A2 (en)	2011-10-06
BRPI1009381B8 (pt)	2021-05-25
EP2411395A1 (fr)	2012-02-01
JP2012521407A (ja)	2012-09-13
IL215177A (en)	2014-01-30
BRPI1009381B1 (pt)	2020-04-14
KR101524337B1 (ko)	2015-05-29
SG184769A1 (en)	2012-10-30
SI2411396T1 (sl)	2013-07-31
US8987278B2 (en)	2015-03-24
ZA201107649B (en)	2012-07-25
DK2411395T3 (da)	2013-08-05
SG184767A1 (en)	2012-10-30
SG174398A1 (en)	2011-10-28
AU2010227225A1 (en)	2011-09-15
DK2634191T3 (en)	2015-03-23
WO2010109334A3 (fr)	2010-11-25
PT2411395E (pt)	2013-06-06
PE20120834A1 (es)	2012-07-25
US20150150876A1 (en)	2015-06-04
CN102361877A (zh)	2012-02-22
PE20120775A1 (es)	2012-06-27
MX2011009822A (es)	2012-01-25
JP5612070B2 (ja)	2014-10-22
KR20120004422A (ko)	2012-01-12
ES2424341T3 (es)	2013-10-01
PL2411395T3 (pl)	2013-10-31
US9474758B2 (en)	2016-10-25
SI2411395T1 (sl)	2013-07-31
CN102361877B (zh)	2014-05-07
US20120178766A1 (en)	2012-07-12
EA201190138A1 (ru)	2013-05-30
EP2411396B1 (fr)	2013-05-29
CA2756536C (fr)	2015-10-06
KR20110128898A (ko)	2011-11-30
JP2012521406A (ja)	2012-09-13
HK1166074A1 (en)	2012-10-19
ES2424342T3 (es)	2013-10-01
AP2011005889A0 (en)	2011-10-31
CN103755720B (zh)	2016-07-06
AU2010227230A1 (en)	2011-09-22

Publication	Publication Date	Title
AP2948A (en)	2014-07-31	Thienopyrmidinedione derivatives as TRPA1 modulators
ZA201107646B (en)	2012-06-25	Isothiazolo-prrimidinedione derivatives as trpa1 modulators
AP3280A (en)	2015-05-31	Fused pyrimidine-dione derivatives as TRPA1 modulators
IL219087A0 (en)	2012-06-28	Benzimidazole-imidazole derivatives
IL217956A0 (en)	2012-03-29	N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en)	2012-03-29	5-fluoropyrimidinone derivatives
IL215169A0 (en)	2011-12-29	Isoxazole -pyridine derivatives as gaba modulators
IL216007A0 (en)	2012-01-31	Isoxazole-pyridine derivatives
IL215109A0 (en)	2011-12-29	Isoxazole-pyridazine derivatives
IL214941A0 (en)	2011-11-30	Isoxazole-pyrazole derivatives
IL217952A0 (en)	2012-03-29	N1-acyl-5-fluoropyrimidinone derivatives
IL213927A0 (en)	2011-07-31	Deoxyactagardine derivatives
IL216761A0 (en)	2012-02-29	Pyrazinooxazepine derivatives
GB0921967D0 (en)	2010-02-03	Novel Aryloxyanilide Derivatives
IL213262A0 (en)	2011-07-31	Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en)	2009-08-26	Indopyl-pyridone derivatives
AP2011005883A0 (en)	2011-10-31	Furopyrimidinedione derivatives as TRPA1 modulators.